Skip to main content

Table 4 Drug-resistant profiles of new patients stratified by age groups

From: Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study

 

15–34

(n = 666)

35–59

(n = 1318)

≥60

(n = 1736)

Total

(n = 3720)

p-value

Any drug resistance

91 (13.7%)

189 (14.3%)

230 (13.2%)

510 (13.7%)

0.685

Resistant to

 INH

62 (9.3%)

140 (10.6%)

153 (8.8%)

355 (9.5%)

0.236

 RIF

41 (6.2%)

54 (4.1%)

42 (2.4%)

137 (3.7%)

0.000

 Rfb

31 (4.7%)

33 (2.5%)

28 (1.6%)

92 (2.5%)

0.000

 EMB

15 (2.3%)

38 (2.9%)

29 (1.7%)

82 (2.2%)

0.077

 PZA

11 (1.7%)

22 (1.7%)

21 (1.2%)

54 (1.5%)

0.514

 Km

2 (0.3%)

5 (0.4%)

11 (0.6%)

18 (0.5%)

0.455

 Am

2 (0.3%)

5 (0.4%)

10 (0.6%)

17 (0.5%)

0.584

 Cm

3 (0.5%)

5 (0.4%)

15 (0.9%)

23 (0.6%)

0.198

 Sm

26 (3.9%)

46 (3.5%)

59 (3.4%)

131 (3.5%)

0.832

 Lfx

8 (1.2%)

18 (1.4%)

18 (1.0%)

44 (1.2%)

0.706

 Mfx

7 (1.1%)

14 (1.1%)

17 (1.0%)

38 (1.0%)

0.971

 Ofx

8 (1.2%)

18 (1.4%)

17 (1.0%)

43 (1.2%)

0.608

 Pto

6 (0.9%)

6 (0.5%)

18 (1.0%)

30 (0.8%)

0.196

 Cs

0 (0.0%)

1 (0.1%)

1 (0.1%)

2 (0.1%)

0.785

 PAS

3 (0.5%)

14 (1.1%)

24 (1.4%)

41 (1.1%)

0.145

INH-monoresistance

36 (5.4%)

99 (7.5%)

122 (7.0%)

257 (6.9%)

0.210

RIF-monoresistance

15 (2.3%)

13 (1.0%)

11 (0.6%)

39 (1.0%)

0.002

Multidrug resistance

26 (3.9%)

41 (3.1%)

31 (1.8%)

98 (2.6%)

0.006

Resistance to any FQsa

9 (1.4%)

18 (1.4%)

18 (1.0%)

45 (1.2%)

0.666

Resistance to any SLIDsb

5 (0.8%)

6 (0.5%)

17 (1.0%)

28 (0.8%)

0.252

  1. Abbreviations: INH isoniazid, RIF rifampicin, Rfb rifabutin, EMB ethambutol, PZA pyrazinamide, Km kanamycin, Am amikacin, Cm capreomycin, Sm streptomycin, Lfx levofloxacin, Mfx moxifloxacin, Ofx ofloxacin, Pto prothionamide, Cs cycloserine, PAS para-aminosalicylic acid, FQs fluoroquinolones, SLIDs second-line injectable drugs
  2. aAny fluoroquinolones refer to levofloxacin, moxifloxacin, or ofloxacin
  3. bAny second-line injectable drugs refer to kanamycin, amikacin, or capreomycin